Tesamorelin is a stabilized synthetic peptide analogue of the hypothalamic peptide, Growth Hormone Releasing Hormone (GHRH) indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Lipodystrophy is a metabolic condition characterized by insulin resistance, fat redistribution, and hyperlipidemia associated with antiretroviral therapy for HIV infection.
One of the most effective GH releasing peptides on the market. Increases IGF-1 levels, lowers visceral fat.
All peptides are sold as research material – not for human consumption.
This is the same peptide that is in the product called Egrifta.
“Egrifta can harm an unborn baby or cause birth defects. Do not use Egrifta if you are pregnant. Tell your doctor right away if you become pregnant during treatment. Women with HIV or AIDS should not breast feed a baby. Even if your baby is born without HIV, the virus may be passed to the baby in your breast milk. Do not give Egrifta to a child without medical advice.”